| Previous Close | 81.73 |
| Open | 82.06 |
| Bid | 82.03 x 400 |
| Ask | 82.20 x 200 |
| Day's Range | 81.39 - 82.42 |
| 52 Week Range | 64.18 - 86.72 |
| Volume | 2,849,924 |
| Avg. Volume | 3,484,629 |
| Market Cap | 85.88B |
| Beta | 0.12 |
| PE Ratio (TTM) | 35.49 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.52%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
- Barrons.com•5 days ago
[$$] 4 Buys in a Watchful Market
Eli Lilly • LLY-NYSE Long-Term Buy • Price $82.17 on Sept. 12 by Hilliard Lyons At the European Society for Medical Oncology Annual Congress, Lilly presented strong data from a key trial on its cancer drug Abemaciclib. As a reminder to investors, while cross-trial comparisons are difficult to make, the presentation provided physicians and investors the best opportunity to compare Abemaciclib to the other CDK4/6 inhibitors, and we think it can take some market share from competitors in this niche.
- TheStreet.com•5 days ago
Eli Lilly Still Looking for Lower Prices
The charts don't look positive for drug company Eli Lilly.
- Investor's Business Daily•5 days ago
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Theravance and Exelixis tick off most of the acquisition boxes for Big Pharma, an analyst said Friday.
